česky english polski


: myRisk | 3 new genes in myRisk test

Myriad included additional 3 genes (POLD1, POLE a GREM1) into his multigenic panel myRisk.                  https://www.myriadpro.com/new-myrisk-genes


: JNCI Oxford Journal - direct comparison of Endopredict & Oncotyped Dx

Head – to Head Breast Cancer study demonstrated that EndoPredict more accurately predicted the recurrence of breast cancer up to 10 years after diagnosis in patients with ER+, HER2- breast cancer than  Oncotype Dx.


: EndoPredict | Myriad Acquires Sividon Diagnostics

Sividon Acquisition Press Release

: EndoPredict is included in updated ASCO guidelines.


: San Antonio Breast Cancer Symposium 2015

Lecture: Mitchell Dowsett, December 10,  9.30 AM

EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the Oncotype DX recurrence score (RS)“


: ESMO guidelines

September 2015:  In its recently published ”Clinical Practice Guidelines”  the European Society for Medical Oncology (ESMO) advocates the use of the EndoPredict gene expression test for primary diagnosis in breast cancer patients.